With box warnings

Without box warnings

Branded

Generic

3 results

eliquis
(apixaban)
E.R. Squibb & Sons, L.L.C.
Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.
savaysa
(EDOXABAN TOSYLATE)
Daiichi Sankyo Inc.
Usage: SAVAYSA is indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for treating deep vein thrombosis and pulmonary embolism after initial therapy with a parenteral anticoagulant. It should not be used in patients with CrCL > 95 mL/min.
xarelto
(rivaroxaban)
Janssen Pharmaceuticals, Inc.
Usage: XARELTO is indicated for reducing the risk of stroke in nonvalvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), preventing DVT after hip or knee replacement, and reducing major cardiovascular events in coronary artery disease. It's also used in pediatric patients for VTE treatment and prevention.

Factor Xa Inhibitor class drugs

eliquis